GlassScriptPhysician profile
Erin E Creps
NPI 1265168421
$1,683.76
in general payments reported to CMS, 2019-2025
23 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $806 · 2024: $489 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496 · Education: $188.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.76 |
| Education | $188.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $361.67 | 2023-2025 | |
| Astellas Pharma US INC | $337.96 | 2023-2025 | Veozah |
| Sumitomo Pharma America, INC. | $163.00 | 2023 | Myfembree |
| Pfizer INC. | $115.31 | 2023-2025 | |
| Sage Therapeutics, LLC | $95.31 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $66.15 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Exeltis, USA INC. | $62.64 | 2024-2025 | Slynd |
| Organon LLC | $61.55 | 2023-2024 | Nexplanon |
| Lilly USA, LLC | $59.86 | 2024 | Zepbound, Mounjaro, Jardiance |
| Idorsia Pharmaceuticals US INC | $57.86 | 2023-2024 | Quviviq |
| Mayne Pharma Commercial LLC | $44.05 | 2023-2024 | |
| Innovation Technologies INC | $34.48 | 2023 | Irrisept |
| Currax Pharmaceuticals LLC | $31.64 | 2023 | Contrave, Nexlizet, Nexletol |
| Glaxosmithkline, LLC. | $29.70 | 2023 | Arexvy, Shingrix, Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $23.12 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $20.74 | 2025 | Qelbree |
| Dexcom, INC. | $19.58 | 2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $18.78 | 2024 | Korlym |
| Mimedx Group, INC. | $17.14 | 2025 | |
| Amgen INC. | $16.32 | 2024 | Otezla, Repatha |
| Zimmer Biomet Holdings, INC. | $16.02 | 2024 | Cellentra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.52 | 2023 | Jardiance |
| Exact Sciences Corporation | $15.36 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Creps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.